Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluticasone propionate + salmeterol or budesonide + formoterol
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Inhalation
01
Overview
This entry refers to two alternative fixed-dose combination inhalers used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD): fluticasone propionate + salmeterol and budesonide + formoterol. Both combinations pair an inhaled corticosteroid (ICS) with a long-acting beta2-adrenergic agonist (LABA). The ICS component (fluticasone propionate or budesonide) reduces airway inflammation by inhibiting multiple types of inflammatory cells and mediators. The LABA component (salmeterol or formoterol) relaxes bronchial smooth muscle via selective stimulation of beta2-adrenergic receptors in the airway, leading to bronchodilation. These combinations are not intended for acute symptom relief but are used as controller medications to reduce exacerbations and improve lung function in patients with persistent asthma or COPD[1][2][6].
- Brand names
- Advair DiskusAdvair HFAWixela InhubAirDuo DigihalerSymbicort
- Other names
- fluticasone and salmeterolbudesonide and formoterol
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on fluticasone propionate + salmeterol or budesonide + formoterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluticasone propionate + salmeterol or budesonide + formoterol.